Lilly’s Lepodisiran Slashes Heart Disease Risk Factor by 94% in Phase 2 Trial
Eli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read moreEli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read moreLexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin therapy in development for
Read moreNovartis has received its third U.S. Food and Drug Administration (FDA) approval for Fabhalta® (iptacopan), marking a major milestone as
Read moreThe CTAT Enzymatic Antibody Drug Conjugation Technology -Benefits for Diagnostic Applications and ADC’s for Oncology. A Biosynth Case Study This
Read moreIn a significant move to expand its oncology portfolio, Taiho Pharmaceutical Co., Ltd. has entered a definitive agreement to fully
Read moreA groundbreaking study by Groh et al., recently featured in Nature Communications, delves into the interplay between adaptive immunity and
Read moreDarkAdapt, an advanced extension of the OptoDrum system, enables precise and reproducible studies with dark-adapted rodents. This innovative instrument provides
Read moreCutting-edge CacoReady Cell-based Plates with pre-developed Caco-2 cells for in vitro permeability assessment have been a key tool in a
Read moreBioEcho has developed a new range of rapid viral RNA/DNA extraction kits designed for a one-step extraction of viral RNA
Read moreGroundbreaking research from Harvard Medical School indicates that vision loss caused by optic nerve damage, glaucoma, and aging may not
Read more